Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.

Companies that are successful do not need to change their name, therapeutic area or product focus.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.

An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.

Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.

The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.

Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.

Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.

The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.

AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.

In Trop2 Merck & Co. might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.

In this week's podcast edition of Five Must-Know Things: a preview of ASCO; Roche CEO on new opportunities; Sanofi sees success in MS; Phase II lupus win for AbbVie; and a Chinese product case study in psoriasis.

New data with a novel RNA translation regulator gave the stock a pre-ASCO boost, but the micro-cap company needs to keep the momentum going.

AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.

There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 antibody-drug conjugate, but no such good news for Zai Lab’s zolbetuximab challenger.

The company said it is in talks with the US FDA for an accelerated approval filing of the HER2-directed bispecific antibody, which showed better ORR and PFS than the standard of care.

Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.

An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.